Search Results

You are looking at 131 - 140 of 183 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Suzanne C. O'Neill, Claudine Isaacs, Calvin Chao, Huei-Ting Tsai, Chunfu Liu, Bola F. Ekezue, Nandini Selvam, Larry G. Kessler, Marc D. Schwartz, Tania Lobo, and Arnold L. Potosky

Cuzick J Wale C . Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study . J Clin Oncol 2010

Full access

Traci LeMasters, S. Suresh Madhavan, Usha Sambamoorthi, Hannah W. Hazard-Jenkins, Kimberly M. Kelly, and Dustin Long

. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer . N Engl J Med 2004 ; 351 : 971 – 977 . 11. Hughes KS Schnaper LA Bellon JR . Lumpectomy plus tamoxifen with or without irradiation

Full access

Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel

women who are BRCA -positive. 6 Retrospective studies of BRCA carriers indicate that adjuvant tamoxifen 7 and risk-reduction mastectomy can significantly reduce the risk for new primary breast cancer, up to 50% and 90%, respectively. 8 Risk

Full access

Robert A. Swarm, Judith A. Paice, Doralina L. Anghelescu, Madhuri Are, Justine Yang Bruce, Sorin Buga, Marcin Chwistek, Charles Cleeland, David Craig, Ellin Gafford, Heather Greenlee, Eric Hansen, Arif H. Kamal, Mihir M. Kamdar, Susan LeGrand, Sean Mackey, M. Rachel McDowell, Natalie Moryl, Lisle M. Nabell, Suzanne Nesbit, BCPS, Nina O’Connor, Michael W. Rabow, Elizabeth Rickerson, Rebecca Shatsky, Jill Sindt, Susan G. Urba, Jeanie M. Youngwerth, Lydia J. Hammond, and Lisa A. Gurski

attention to serotonergic medications (eg, SSRIs) due to risk of serotonin syndrome. Several antidepressants are known inhibitors of hepatic drug metabolism via inhibition of cytochrome P450 enzymes, especially CYP2D6. Tamoxifen is an estrogen receptor

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian, and Maoko Naganuma

undergoing chemotherapy. Increased VTE risk was shown to be associated with the use of exogenous hormonal compounds, such as selective estrogen receptor modulators (eg, tamoxifen, raloxifene), for the prevention and treatment of certain estrogen receptor

Full access

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

a clinical relapse is 2 to 6 months. A lack of consensus exists regarding the timing of recurrence therapy for patients who have undergone previous chemotherapy. Because tamoxifen and other hormonally active agents have a defined response rate in

Full access

Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Amro Elshoury, John Fanikos, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Ibrahim Ibrahim, Eric Kraut, Andrew D. Leavitt, Alfred Lee, Jason T. Lee, Ming Lim, Janelle Mann, Karlyn Martin, Brandon McMahon, John Moriarty, Colleen Morton, Thomas L. Ortel, Rita Paschal, Jordan Schaefer, Sanford Shattil, Tanya Siddiqi, Deepak Sudheendra, Eliot Williams, Liz Hollinger, and Mai Q. Nguyen

erythropoietic stimulating agents (ESAs). Exogenous hormonal compounds, such as selective estrogen receptor modulators (eg, tamoxifen, raloxifene for breast cancer) can lead to increased VTE risk. 92 – 96 Diethylstilbestrol phosphate used in combination with

Full access

Peter F. Coccia, Alberto S. Pappo, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, A. Lindsay Frazier, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Brad Zebrack, Dorothy A. Shead, and Hema Sundar

history of breast cancer, although for women treated with tamoxifen, levonorgestrel-containing intrauterine system (IUS) may be preferable because it has been shown to reduce tamoxifen-induced endometrial changes without increasing the risk of breast

Full access

Scott V. Bratman, Kathleen C. Horst, Robert W. Carlson, and Daniel S. Kapp

treatment break was required to allow for healing after the patient developed moist desquamation on the chest wall. Tamoxifen was initiated after radiotherapy and continues at the time of writing. 7 At 57 months after surgery, the patient has remained

Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen [abstract] . J Clin Oncol 2008 ; 26 ( Suppl ): Abstract 564 . 17. Van Poznak C Hannon R Clack G . Managing cancer treatment